We are live on ! Find out more
VTYX

Ventyx Biosciences

Delisted

VTYX was delisted on the 3rd of March, 2026.

121 hedge funds and large institutions have $112M invested in Ventyx Biosciences in 2023 Q4 according to their latest regulatory filings, with 45 funds opening new positions, 31 increasing their positions, 33 reducing their positions, and 61 closing their positions.

New
Increased
Maintained
Reduced
Closed

6% less repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 33

12% less funds holding

Funds holding: 138121 (-17)

16.19% less ownership

Funds ownership: 92.69%76.5% (-16%)

26% less first-time investments, than exits

New positions opened: 45 | Existing positions closed: 61

67% less funds holding in top 10

Funds holding in top 10: 31 (-2)

86% less call options, than puts

Call options by funds: $426K | Put options by funds: $2.95M

94% less capital invested

Capital invested by funds: $1.9B → $112M (-$1.78B)

Holders
121
Holders Change
-17
Holders Change %
-12.32%
% of All Funds
1.76%
Holding in Top 10
1
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-66.67%
% of All Funds
0.01%
New
45
Increased
31
Reduced
33
Closed
61
Calls
$426K
Puts
$2.95M
Net Calls
-$2.52M
Net Calls Change
-$1.6M
Name Holding Trade Value Shares
Change
Change in
Stake
DCM
126
Driehaus Capital Management
Illinois
-$38.5M -1,107,631 Closed
T. Rowe Price Investment Management
127
T. Rowe Price Investment Management
Maryland
-$35.9M -1,032,846 Closed
Pictet Asset Management
128
Pictet Asset Management
Switzerland
-$33.7M -969,979 Closed
BC
129
Boxer Capital
California
-$29.5M -850,000 Closed
VP
130
venBio Partners
California
-$26.4M -758,800 Closed
VC
131
Vivo Capital
California
-$14.7M -422,075 Closed
AG
132
Artal Group
Luxembourg
-$14.1M -405,239 Closed
APM
133
Avidity Partners Management
Texas
-$12.3M -354,900 Closed
O
134
OrbiMed
New York
-$11.8M -340,384 Closed
GC
135
GMT Capital
Georgia
-$9.75M -280,600 Closed
JFG
136
Jefferies Financial Group
New York
-$9.5M -273,574 Closed
Victory Capital Management
137
Victory Capital Management
Texas
-$9.02M -259,634 Closed
Hudson Bay Capital Management
138
Hudson Bay Capital Management
Connecticut
-$8.63M -248,515 Closed
Balyasny Asset Management
139
Balyasny Asset Management
Illinois
-$7.54M -217,151 Closed
ACP
140
Acuta Capital Partners
California
-$7.13M -205,377 Closed
WP
141
Woodline Partners
California
-$7.08M -203,783 Closed
TD Asset Management
142
TD Asset Management
Ontario, Canada
-$5.4M -155,408 Closed
NCM
143
Nantahala Capital Management
Connecticut
-$5.13M -147,623 Closed
PCM
144
Peregrine Capital Management
Minnesota
-$3.28M -94,565 Closed
MCMC
145
Matrix Capital Management Company
New Hampshire
-$3.12M -89,900 Closed
SAM
146
Sectoral Asset Management
Quebec, Canada
-$3.06M -88,000 Closed
UOC
147
UBS O'Connor
Illinois
-$432K -45,463 Closed
AA
148
ALPS Advisors
Colorado
-$1.51M -43,437 Closed
TIAA Trust, National Association
149
TIAA Trust, National Association
North Carolina
-$1.45M -41,875 Closed
MAP
150
Moody Aldrich Partners
Massachusetts
-$1.32M -37,988 Closed

VTYX Hedge Fund Activity: Q4 2023 in Review

121 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Ventyx Biosciences (VTYX) for Q4 2023, worth a combined $112M — down 94% from $1.9B a quarter earlier.

Sellers outnumbered buyers: 61 funds closed out of VTYX and 45 opened new positions — a net loss of 16 holders — while 33 trimmed existing stakes and 31 added.

The largest buyer was Morgan Stanley, adding an estimated $33.7M. The largest seller was Fidelity Investments, cutting an estimated $81.8M.

  • 121 institutional investors held Ventyx Biosciences (VTYX) as of Q4 2023, down from 138 in Q3 2023.
  • Funds reported $112M of Ventyx Biosciences stock for Q4 2023, down 94% quarter-over-quarter.
  • 45 funds opened new Ventyx Biosciences positions in Q4 2023 and 61 closed out, a net change of -16 holders.
  • The largest Ventyx Biosciences buyer in Q4 2023 was Morgan Stanley, an estimated $33.7M added.
  • The largest Ventyx Biosciences seller in Q4 2023 was Fidelity Investments, an estimated $81.8M sold.

Based on aggregated 13F filings for Q4 2023.